Omeros files OMS721 orphan drug application with FDA
OMS721 works by blocking the lectin pathway of the complement system while leaving intact the classical pathway and selectively inhibits MASP-2 representing the acquired immune response to infection.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.